SiRNA-based therapies for pulmonary diseases

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 1953-1997

  Koli, Uday ^a   Krishnan, R Akhil ^a   Pofali, Prasad ^a   Jain, Ratnesh ^a   Dandekar, Prajakta ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Asthma; COPD; Infections; Lung cancer; Nanocarrier; Non Viral; Pulmonary delivery; Routes; siRNA

Indexed keywords

BIOLOGICAL ORGANS; ENZYME INHIBITION;

ASTHMA; COPD; INFECTIONS; LUNG CANCER; NANOCARRIERS; NONVIRAL; PULMONARY DELIVERY; ROUTES; SIRNA;

PULMONARY DISEASES;

NANOCARRIER; SMALL INTERFERING RNA; DRUG CARRIER;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE SILENCING; HUMAN; LUNG CANCER; LUNG DISEASE; NONHUMAN; REVIEW; TUBERCULOSIS; ADVERSE EFFECTS; ANIMAL; CHEMISTRY; GENE THERAPY; GENE TRANSFER; LEGISLATION AND JURISPRUDENCE; LUNG; LUNG DISEASES; METABOLISM;

ANIMALS; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LUNG; LUNG DISEASES; RNA, SMALL INTERFERING;

EID: 84904907450     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1928     Document Type: Review

References (411)

1. C. D. Novina and P. A. Sharp, The rnai revolution. Nature 430, 161 (2004).
2. G. J. Hannon, RNA interference. Nature 418, 244 (2002).
3. M. T. McManus and P. A. Sharp, Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3, 737 (2002).
4. S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494 (2001).
5. M. Tijsterman and R. H. Plasterk, Dicers at RISC: The mechanism of RNAi. Cell 117, 1 (2004).
6. M. A. Behlke, Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644 (2006).
7. K. Tiemann and J. J. Rossi, RNAi-based therapeutics - current status, challenges and prospects. EMBO Mol. Med. 1, 142 (2009).
8. D. W. Sah, Therapeutic potential of RNA interference for neurological disorders. Life Sci. 79, 1773 (2006).
9. S. Akhtar and I. F. Benter, Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117, 3623 (2007).
10. J. Gil and M. Esteban, Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): Mechanism of action. Apoptosis 5, 107 (2000).
11. M. Kumar and G. G. Carmichael, Antisense RNA: Function and fate of duplex RNA in cells of higher eukaryotes. Microbiol. Mol. Biol. Rev. 62, 1415 (1998).
12. D. D. Rao, J. S. Vorhies, N. Senzer, and J. Nemunaitis, siRNA versus shRNA: Similarities and differences. Adv. Drug Deliv. Rev. 61, 746 (2009).
13. M. Schlee, V. Hornung, and G. Hartmann, siRNA and isRNA: Two edges of one sword. Mol. Ther. 14, 463 (2006).
14. K. Singha, R. Namgung, and W. J. Kim, Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 21, 133 (2011).
15. M. Ichihara, Y. Murakumo, A. Masuda, T. Matsuura, N. Asai, M. Jijiwa, M. Ishida, J. Shinmi, H. Yatsuya, and S. Qiao, Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. Nucleic Acids Res. 35, e123 (2007).
16. F. M. Van de Water, O. C. Boerman, A. C. Wouterse, J. G. Peters, F. G. Russel, and R. Masereeuw, Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 34, 1393 (2006).
17. D. Castanotto and J. J. Rossi, The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426 (2009).
18. R. Juliano, M. R. Alam, V. Dixit, and H. Kang, Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36, 4158 (2008).
19. S. Mukherjee, R. N. Ghosh, and F. R. Maxfield, Endocytosis. Physiol. Rev. 77, 759 (1997).
20. L. Medina-Kauwe, J. Xie, and S. Hamm-Alvarez, Intracellular trafficking of nonviral vectors. Gene Ther. 12, 1734 (2005).
21. A. Aderem and D. M. Underhill, Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17, 593 (1999).
22. A. Vonarbourg, C. Passirani, P. Saulnier, and J.-P. Benoit, Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27, 4356 (2006).
23. D. E. Owens, III and N. A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93 (2006).
24. H. Hillaireau and P. Couvreur, Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol. Life Sci. 66, 2873 (2009).
25. Y. Wang and L. Huang, A window onto siRNA delivery. Nat. Biotechnol. 31, 611 (2013).
26. D. V. Morrissey, J. A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, and V. Jadhav, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002 (2005).
27. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, and J. Harborth, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173 (2004).
28. A. G. Rosas-Taraco, D. M. Higgins, J. Sánchez-Campillo, E. J. Lee, I. M. Orme, and M. González-Juarrero, Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 41, 136 (2009).
29. T. Senoo, N. Hattori, T. Tanimoto, M. Furonaka, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, A. Yokoyama, and N. Kohno, Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax. 65, 334 (2010).
30. C.-X. Xu, D. Jere, H. Jin, S.-H. Chang, Y.-S. Chung, J.-Y. Shin, J.-E. Kim, S.-J. Park, Y.-H. Lee, and C.-H. Chae, Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am. J. Respir. Crit. Care Med. 178, 60 (2008).
31. S. A. Moschos, S. W. Jones, M. M. Perry, A. E. Williams, J. S. Erjefalt, J. J. Turner, P. J. Barnes, B. S. Sproat, M. J. Gait, and M. A. Lindsay, Lung delivery studies using siRNA conjugated to TAT (48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem. 18, 1450 (2007).
32. O. M. Merkel, A. Beyerle, D. Librizzi, A. Pfestroff, T. M. Behr, B. Sproat, P. J. Barth, and T. Kissel, Nonviral siRNA delivery to the lung: Investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 6, 1246 (2009).
33. B. Gutbier, S. M. Kube, K. Reppe, A. Santel, C. Lange, J. Kaufmann, N. Suttorp, and M. Witzenrath, RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. Pulm. Pharmacol. Ther. 23, 334 (2010).
34. B. Ghosn, A. Singh, M. Li, A. V. Vlassov, C. Burnett, N. Puri, and K. Roy, Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 20, 163 (2010).
35. X. Zhang, P. Shan, D. Jiang, P. W. Noble, N. G. Abraham, A. Kappas, and P. J. Lee, Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279, 10677 (2004).
36. M. Perl, C.-S. Chung, J. Lomas-Neira, T.-M. Rachel, W. L. Biffl, W. G. Cioffi, and A. Ayala, Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am. J. Pathol. 167, 1545 (2005).
37. K. A. Howard, U. L. Rahbek, X. Liu, C. K. Damgaard, S. Z. Glud, M.Ø. Andersen, M. B. Hovgaard, A. Schmitz, J. R. Nyengaard, and F. Besenbacher, RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476 (2006).
38. J. L. Lomas-Neira, C.-S. Chung, D. E. Wesche, M. Perl, and A. Ayala, In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J. Leukoc. Biol. 77, 846 (2005).
39. O. B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A. A. Vetcher, V. A. Soldatenkov, D. C. Reimer, V. P. Pozharov, and T. Minko, Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. 26, 382 (2009).
40. J.-C. Wang, S. Lai, X. Guo, X. Zhang, B. de Crombrugghe, S. Sonnylal, F. Arnett, and X. Zhou, Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res. Ther. 12, R60 (2010).
41. J. Xu, L. Li, J. Hong, and W. Huang, Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: Evidence for non-synergetic cooperation. Cell Biol. Int. 31, 88 (2007).
42. X. Li, J. Zhang, M. Lu, Y. Yang, C. Xu, H. Li, G. Wang, C. Cai, and G. Chen, Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch. Surg. 392, 345 (2007).
43. X. Zhang, X. Zheng, H. Sun, B. Feng, G. Chen, C. Vladau, M. Li, D. Chen, M. Suzuki, and L. Min, Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation 82, 1728 (2006).
44. L. Zender and S. Kubicka, Target Discovery and Validation Reviews and Protocols, edited by Mouldy Sioud, Humana Press Inc., Totowa, NJ (2007), Vol. 1, pp. 217-226.
45. D. Shin, S. I. Kim, M. Kim, and M. Park, Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Res. 119, 146 (2006).
46. T. Hino, T. Yokota, S. Ito, K. Nishina, Y.-S. Kang, S. Mori, S. Hori, T. Kanda, T. Terasaki, and H. Mizusawa, In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem. Biophys. Res. Commun. 340, 263 (2006).
47. J. A. Wolff and V. Budker, The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 1 (2005).
48. M. A. Behlke, Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305 (2008).
49. M. Gaglione and A. Messere, Recent progress in chemically modified siRNAs. Mini Rev. Med. Chem. 10, 578 (2010).
50. J. B. Bramsen and J. Kjems, Antiviral RNAi: Concepts, Methods and Applications, edited by R. P. Van Rij, Humana Press Inc., New York (2011), Vol. 721, pp. 77-103.
51. A. M. Krieg and C. Stein, Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein?. Antisense Res. Dev. 5, 241 (1995).
52. M. Amarzguioui, T. Holen, E. Babaie, and H. Prydz, Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589 (2003).
53. D. A. Braasch, S. Jensen, Y. Liu, K. Kaur, K. Arar, M. A. White, and D. R. Corey, RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42, 7967 (2003).
54. Y.-L. Chiu and T. M. Rana, siRNA function in RNAi: A chemical modification analysis. RNA. 9, 1034 (2003).
55. S. Choung, Y. J. Kim, S. Kim, H.-O. Park, and Y.-C. Choi, Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342, 919 (2006).
56. J. Harborth, S. M. Elbashir, K. Vandenburgh, H. Manninga, S. A. Scaringe, K. Weber, and T. Tuschl, Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13, 83 (2003).
57. Z.-Y. Li, H. Mao, D. A. Kallick, and D. G. Gorenstein, The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem. Biophys. Res. Commun. 329, 1026 (2005).
58. D. A. Braasch, Z. Paroo, A. Constantinescu, G. Ren, O. K. Öz, R. P. Mason, and D. R. Corey, Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14, 1139 (2004).
59. A. H. Hall, J. Wan, E. E. Shaughnessy, B. R. Shaw, and K. A. Alexander, RNA interference using boranophosphate siRNAs: Structure-activity relationships. Nucleic Acids Res. 32, 5991 (2004).
60. F. Czauderna, M. Fechtner, S. Dames, H. Aygün, A. Klippel, G. J. Pronk, K. Giese, and J. Kaufmann, Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705 (2003).
61. A. L. Jackson, S. R. Bartz, J. Schelter, S. V. Kobayashi, J. Burchard, M. Mao, B. Li, G. Cavet, and P. S. Linsley, Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635 (2003).
62. O. Snøve Jr and J. J. Rossi, Chemical modifications rescue off-target effects of RNAi. ACS Chem. Biol. 1, 274 (2006).
63. T. P. Prakash, C. R. Allerson, P. Dande, T. A. Vickers, N. Sioufi, R. Jarres, B. F. Baker, E. E. Swayze, R. H. Griffey, and B. Bhat, Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247 (2005).
64. J. M. Layzer, A. P. Mccaffrey, A. K. Tanner, Z. Huang, M. A. Kay, and B. A. Sullenger, In vivo activity of nuclease-resistant siRNAs. RNA 10, 766 (2004).
65. J. Elmén, H. Thonberg, K. Ljungberg, M. Frieden, M. Westergaard, Y. Xu, B. Wahren, Z. Liang, H. Ørum, and T. Koch, Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439 (2005).
66. S. Z. Glud, J. B. Bramsen, F. Dagnæs-Hansen, J. Wengel, K. A. Howard, J. R. Nyengaard, and J. Kjems, Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 19, 163 (2009).
67. B. D. Chithrani and W. C. Chan, Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7, 1542 (2007).
68. B. D. Chithrani, A. A. Ghazani, and W. C. Chan, Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662 (2006).
69. W. Jiang, B. Y. Kim, J. T. Rutka, and W. C. Chan, Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3, 145 (2008).
70. A. E. Nel, L. Mädler, D. Velegol, T. Xia, E. M. Hoek, P. Somasundaran, F. Klaessig, V. Castranova, and M. Thompson, Understanding biophysicochemical interactions at the nanobio interface. Nat. Mater. 8, 543 (2009).
71. W. C. Hinds (ed.), Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles, John Wiley & Sons, Los Angeles, CA (2012).
72. C. F. Schiller, J. Gebhart, J. Heyder, G. Rudolf, and W. Stahlhofen, Deposition of monodisperse insoluble aerosol particles in the 0.005 to 0.2 μm size range within the human respiratory tract. Ann. Occup. Hyg. 32, 41 (1988).
73. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release 114, 100 (2006).
74. O. Harush-Frenkel, N. Debotton, S. Benita, and Y. Altschuler, Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353, 26 (2007).
75. O. Harush-Frenkel, E. Rozentur, S. Benita, and Y. Altschuler, Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9, 435 (2008).
76. I. Bravo-Osuna, C. Vauthier, A. Farabollini, G. F. Palmieri, and G. Ponchel, Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 28, 2233 (2007).
77. A. Vila, A. Sanchez, M. Tobio, P. Calvo, and M. Alonso, Design of biodegradable particles for protein delivery. J. Control Release 78, 15 (2002).
78. P. Calvo, J. L. Vila-Jato, and M. A. J. Alonso, Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int. J. Pharm. 153, 41 (1997).
79. I. Brigger, J. Morizet, G. Aubert, H. Chacun, M.-J. Terrier-Lacombe, P. Couvreur, and G. Vassal, Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303, 928 (2002).
80. R. Misra, M. Upadhyay, and S. Mohanty, Nanoparticles as carriers for chemotherapeutic drugs: A review. J. Nanopharmaceutics Drug Delivery 1, 103 (2013).
81. S. S. Ferguson, Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1 (2001).
82. Y. Luo, X. Zhai, C. Ma, P. Sun, Z. Fu, W. Liu, and J. Xu, An inhalable β-2-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J. Control Release 162, 28 (2012).
83. S. Ganesh, A. K. Iyer, D. V. Morrissey, and M. M. Amiji, Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 13, 3489 (2013).
84. V. M. Platt and F. C. Szoka, Jr, Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 5, 474 (2008).
85. A. Sharma, S. Sharma, and G. Khuller, Lectin-functionalized poly(lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54, 761 (2004).
86. T. Hoshino, R. Toda, and H. Aizawa, Pharmacological treatment in asthma and COPD. Allergol Int. 58, 341 (2009).
87. M. Kampelmacher, R. Van Kesteren, G. Alsbach, C. Melissant, H. Wynne, J. Douze, and J. Lammers, Characteristics and complaints of patients prescribed long-term oxygen therapy in The Netherlands. Respir. Med. 92, 70 (1998).
88. Drug Information Online, http://www.drugs.com/, Accessed January 3 (2014).
89. M. G. Cosio, M. Saetta, and A. Agusti, Immunologic aspects of chronic obstructive pulmonary disease. N. Engl. J. Med. 360, 2445 (2009).
90. World Health Organisation, http://www.who.int/mediacentre/factsheets/ fs104/en/index.html, Accessed December 3 (2013).
91. R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, 2012. CA. Cancer J. Clin. 62, 10 (2012).
92. D. M. Parkin, Global cancer statistics in the year 2000. Lancet Oncol. 2, 533 (2001).
93. T. Naruke, R. Tsuchiya, H. Kondo, and H. Asamura, Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: The Japanese experience. Ann. Thorac. Surg. 71, 1759 (2001).
94. B. Spänkuch-Schmitt, J. Bereiter-Hahn, M. Kaufmann, and K. Strebhardt, Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94, 1863 (2002).
95. R. Gupta, D. P. Jindal, and G. Kumar, Corticosteroids: The mainstay in asthma therapy. Bioorg. Med. Chem. 12, 6331 (2004).
96. S. D. Li and L. Huang, Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 3, 579 (2006).
97. D. Jere, C.-X. Xu, R. Arote, C.-H. Yun, M.-H. Cho, and C.-S. Cho, Poly(β-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. Biomaterials 29, 2535 (2008).
98. X.-L. Ren, Y.-M. Xu, W. Bao, H.-J. Fu, C.-G. Wu, Y. Zhao, Z.-K. Li, J. Zhang, S.-Q. Li, and W.-Q. Chen, Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Lett. 281, 134 (2009).
99. D. Zamora-Avila, P. Zapata-Benavides, M. Franco-Molina, S. Saavedra-Alonso, L. Trejo-Avila, D. Resendez-Perez, J. Mendez-Vazquez, J. Isaias-Badillo, and C. Rodriguez-Padilla, WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 16, 892 (2009).
100. Q. Ge, L. Filip, A. Bai, T. Nguyen, H. N. Eisen, and J. Chen, Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101, 8676 (2004).
101. B.-J. Li, Q. Tang, D. Cheng, C. Qin, F. Y. Xie, Q. Wei, J. Xu, Y. Liu, B.-J. Zheng, and M. C. Woodle, Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 11, 944 (2005).
102. A. Fulton, S. T. Peters, G. A. Perkins, K. W. Jarosinski, A. Damiani, M. Brosnahan, E. L. Buckles, N. Osterrieder, and G. R. Van de Walle, Effective treatment of respiratory alphaherpesvirus infection using RNA interference. PLoS One 4, e4118 (2009).
103. J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, and A. Vaishnaw, A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 107, 8800 (2010).
104. R. M. Séguin and N. Ferrari, Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 18, 1505 (2009).
105. C. N. D'Alessandro-Gabazza, T. Kobayashi, D. Boveda-Ruiz, T. Takagi, M. Toda, P. Gil-Bernabe, Y. Miyake, A. Yasukawa, Y. Matsuda, and N. Suzuki, Development and Preclinical Efficacy of Novel Transforming Growth Factor-β1 Short Interfering RNAs for Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 46, 397 (2012).
106. S. R. Schmidt, Fusion-proteins as biopharmaceuticals - applications and challenges. Curr. Opin. Drug Discov. Devel. 12, 284 (2009).
107. F. M. Veronese and G. Pasut, PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451 (2005).
108. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke, The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2, 198 (2001).
109. I. Roy and N. Vij, Nanodelivery in airway diseases: Challenges and therapeutic applications. Nanomedicine 6, 237 (2010).
110. M. Sakagami, In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58, 1030 (2006).
111. D. Groneberg, P. Eynott, S. Lim, T. Oates, R. Wu, I. Carlstedt, P. Roberts, B. McCann, A. Nicholson, and B. Harrison, Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology 40, 367 (2002).
112. N. Sanders, C. Rudolph, K. Braeckmans, S. C. De Smedt, and J. Demeester, Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61, 115 (2009).
113. P. K. Jeffery, Remodeling in asthma and chronic obstructive lung disease. American Journal of Respiratory and Critical Care Medicine 164, S28 (2001).
114. C. Marianecci, L. Di Marzio, F. Rinaldi, M. Carafa, and F. Alhaique, Pulmonary delivery: Innovative approaches and perspectives. J. Biomater. Nanobiotechnol. 2, 567 (2011).
115. J. Rosenecker, S. Naundorf, S. Gersting, R. Hauck, A. Gessner, P. Nicklaus, R. Müller, and C. Rudolph, Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: Analysing the role of proteins and glycoproteins. J. Gene. Med. 5, 49 (2003).
116. J. E. Duncan, J. A. Whitsett, and A. D. Horowitz, Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum. Gene Ther. 8, 431 (1997).
117. W. Zauner, N. A. Farrow, and A. M. Haines, In vitro uptake of polystyrene microspheres: Effect of particle size, cell line and cell density. J. Control Release 71, 39 (2001).
118. M. P. Desai, V. Labhasetwar, E. Walter, R. J. Levy, and G. L. Amidon, The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14, 1568 (1997).
119. M. P. Desai, V. Labhasetwar, G. L. Amidon, and R. J. Levy, Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm. Res. 13, 1838 (1996).
120. D. Goula, N. Becker, G. Lemkine, P. Normandie, J. Rodrigues, S. Mantero, G. Levi, and B. Demeneix, Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther. 7, 499 (2000).
121. J. Wang, Z. Lu, M. G. Wientjes, and J. L.-S. Au, Delivery of siRNA therapeutics: Barriers and carriers. AAPS J. 12, 492 (2010).
122. T. Endoh and T. Ohtsuki, Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 61, 704 (2009).
123. M. E. Gonzalez and L. Carrasco, Viroporins. FEBS Lett. 552, 28 (2003).
124. J. M. Costin, J. M. Rausch, R. F. Garry, and W. C. Wimley, Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein. Virol J. 4, 123 (2007).
125. E. J. Kwon, J. M. Bergen, and S. H. Pun, Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles. Bioconjug. Chem. 19, 920 (2008).
126. M. L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, and T. Minko, Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug. Chem. 19, 1396 (2008).
127. M. L. Patil, M. Zhang, O. Taratula, O. B. Garbuzenko, H. He, and T. Minko, Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: Effect of the degree of quaternization and cancer targeting. Biomacromolecules 10, 258 (2009).
128. K. E. Driscoll, D. L. Costa, G. Hatch, R. Henderson, G. Oberdorster, H. Salem, and R. B. Schlesinger, Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: Uses and limitations. Toxicol. Sci. 55, 24 (2000).
129. M. Bivas-Benita, R. Zwier, H. E. Junginger, and G. Borchard, Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 61, 214 (2005).
130. J. K.-W. Lam, W. Liang, and H.-K. Chan, Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 64, 1 (2012).
131. D. Lu and A. J. Hickey, Pulmonary vaccine delivery. Expert Rev. Vaccines 6, 213 (2007).
132. D. Scott, Endotracheal intubation: Friend or foe. Br. Med. J. (Clin. Res. Ed.) 292, 157 (1986).
133. J. Conde, F. Tian, Y. Hernández, C. Bao, D. Cui, K.-P. Janssen, M. R. Ibarra, P. V. Baptista, T. Stoeger, and J. M. de la Fuente, In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 34, 7744 (2013).
134. E. J. Nielsen, J. M. Nielsen, D. Becker, A. Karlas, H. Prakash, S. Z. Glud, J. Merrison, F. Besenbacher, T. F. Meyer, and J. Kjems, Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm. Res. 27, 2520 (2010).
135. V. Bitko, A. Musiyenko, O. Shulyayeva, and S. Barik, Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50 (2004).
136. D. Massaro, G. D. Massaro, and L. B. Clerch, Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L1066 (2004).
137. U. Griesenbach, C. Kitson, S. E. Garcia, R. Farley, C. Singh, L. Somerton, H. Painter, R. L. Smith, D. R. Gill, and S. C. Hyde, Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir. Res. 7, 26 (2006).
138. A. J. Hickey and L. Garcia-Contreras, Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: Relevance to humans. Crit. Rev. Ther. Drug Carrier Syst. 18, 387 (2001).
139. M. Hinchcliffe and L. Illum, Intranasal insulin delivery and therapy. Adv. Drug Deliv. Rev. 35, 199 (1999).
140. J. Heyder, J. Gebhart, G. Rudolf, C. F. Schiller, and W. Stahlhofen, Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J. Aerosol Sci. 17, 811 (1986).
141. A. A. Hussain, Intranasal drug delivery. Adv. Drug Deliv. Rev. 29, 39 (1998).
142. L. D. Mastrandrea and T. Quattrin, Clinical evaluation of inhaled insulin. Adv. Drug Deliv. Rev. 58, 1061 (2006).
143. S. Bai, V. Gupta, and F. Ahsan, Inhalable lactose-based dry powder formulations of low molecular weight heparin. J. Aerosol Med. Pulm. Drug Deliv. 23, 97 (2010).
144. D. M. K. Jensen, D. Cun, M. J. Maltesen, S. Frokjaer, H. M. Nielsen, and C. Foged, Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control Release 142, 138 (2010).
145. D. K. Jensen, L. B. Jensen, S. Koocheki, L. Bengtson, D. Cun, H. M. Nielsen, and C. Foged, Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Control Release 157, 141 (2012).
146. P. Yadava, M. Gibbs, C. Castro, and J. A. Hughes, Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS Pharm. Sci. Tech. 9, 335 (2008).
147. A. K. Kundu, P. K. Chandra, S. Hazari, G. Ledet, Y. V. Pramar, S. Dash, and T. K. Mandal, Stability of lyophilized siRNA nanosome formulations. Int. J. Pharm. 423, 525 (2012).
148. J. C. Kasper, D. Schaffert, M. Ogris, E. Wagner, and W. Friess, Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability-A step closer from promising technology to application. J. Control Release 151, 246 (2011).
149. M.-E. Bonnet, J.-B. Gossart, E. Benoit, M. Messmer, O. Zounib, V. Moreau, J.-P. Behr, N. Lenne-Samuel, V. Kedinger, and A. Meulle, Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J. Control Release 170, 183 (2013).
150. J. McCaskill, R. Singhania, M. Burgess, R. Allavena, S. Wu, A. Blumenthal, and N. A. McMillan, Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol. Ther. Nucleic Acids 2, e96 (2013).
151. J. S. Bertram and P. Janik, Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Letters 11, 63 (1980).
152. F. Kamlah, B. Eul, S. Li, N. Lang, L. Marsh, W. Seeger, F. Grimminger, F. Rose, and J. Hänze, Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther. 16, 195 (2008).
153. S. Moschos, A. Williams, and M. Lindsay, Cell-penetrating-peptide- mediated siRNA lung delivery. Biochem. Soc. Trans. 35, 807 (2007).
154. S. D. Li, S. Chono, and L. Huang, Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942 (2008).
155. K. Miyawaki-Shimizu, D. Predescu, J. Shimizu, M. Broman, S. Predescu, and A. B. Malik, siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L405 (2006).
156. T. I. Novobrantseva, A. Akinc, A. Borodovsky, and A. de Fougerolles, Delivering silence: Advancements in developing siRNA therapeutics. Curr. Opin. Drug Discov. Devel. 11, 217 (2008).
157. I. Narvaiza, O. Aparicio, M. Vera, N. Razquin, S. Bortolanza, J. Prieto, and P. Fortes, Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J. Virol. 80, 12236 (2006).
158. X. Guo, W. Wang, J. Hu, K. Feng, Y. Pan, L. Zhang, and Y. Feng, Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo. Anat. rec. 295, 2114 (2012).
159. C. Shen, A. K. Buck, X. Liu, M. Winkler, and S. N. Reske, Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539, 111 (2003).
160. K. J. Scanlon, Cancer gene therapy: Challenges and opportunities. Anticancer Res. 24, 501 (2004).
161. D. T. Zallen, US gene therapy in crisis. Trends Genet. 16, 272 (2000).
162. A. Musiyenko, V. Bitko, and S. Barik, RNAi-dependent and- independent antiviral phenotypes of chromosomally integrated shRNA clones: Role of VASP in respiratory syncytial virus growth. J. Mol. Med. 85, 745 (2007).
163. S.-D. Li and L. Huang, Non-viral is superior to viral gene delivery. J. Control Release 123, 181 (2007).
164. X.-L. Wang, S. Ramusovic, T. Nguyen, and Z.-R. Lu, Novel polymerizable surfactants with pH-sensitive amphiphilicity and cell membrane disruption for efficient siRNA delivery. Bioconjug. Chem. 18, 2169 (2007).
165. Z. Ma, J. Li, F. He, A. Wilson, B. Pitt, and S. Li, Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755 (2005).
166. S. C. Semple, A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Sah, D. Stebbing, E. J. Crosley, and I. M. Hafez, Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172 (2010).
167. K. Buyens, S. C. De Smedt, K. Braeckmans, J. Demeester, L. Peeters, L. A. van Grunsven, X. de Mollerat du Jeu, R. Sawant, V. Torchilin, K. Farkasova, M. Ogris, and N. N. Sanders, Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. J. Control Release 158, 362 (2012).
168. M. Thomas, J. J. Lu, J. Chen, and A. M. Klibanov, Non-viral siRNA delivery to the lung. Adv. Drug Deliv. Rev. 59, 124 (2007).
169. Y.-C. Tseng, S. Mozumdar, and L. Huang, Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61, 721 (2009).
170. G. Navarro, R. R. Sawant, S. Essex, C. T. de ILarduya, and V. P. Torchilin, Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv. Transl. Res. 1, 25 (2011).
171. G. Navarro, S. Essex, R. R. Sawant, S. Biswas, D. Nagesha, S. Sridhar, C. T. de ILarduya, and V. P. Torchilin, Phospholipid-modified polyethylenimine- based nanopreparations for siRNA-mediated gene silencing: Implications for transfection and the role of lipid components. Nanomedicine 13, pii S1549 (2013).
172. K. Kusumoto, H. Akita, T. Ishitsuka, Y. Matsumoto, T. Nomoto, R. Furukawa, A. El-Sayed, H. Hatakeyama, K. Kajimoto, and Y. Yamada, Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS Nano 7, 7534 (2013).
173. S. Han and J. Roman, Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: Pro-oncogenic effects mediated by PI3-kinase and NF-κB. Oncogene 25, 4341 (2006).
174. M. Sioud and D. R. Sørensen, Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220 (2003).
175. S. Y. Wu and N. A. McMillan, Lipidic systems for in vivo siRNA delivery. AAPS J. 11, 639 (2009).
176. A. J. Bridge, S. Pebernard, A. Ducraux, A.-L. Nicoulaz, and R. Iggo, Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263 (2003).
177. W. Yan, W. Chen, and L. Huang, Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44, 3672 (2007).
178. K. L. Clark, S. A. Hughes, P. Bulsara, J. Coates, K. Moores, J. Parry, M. Carr, R. J. Mayer, P. Wilson, and C. Gruenloh, Pharmacological characterization of a novel ENaCα siRNA (GSK2225745) with potential for the treatment of cystic fibrosis. Mol. Ther. Nucleic Acids 2, e65 (2013).
179. M. X. Shao, I. F. Ueki, and J. A. Nadel, Tumor necrosis factor α-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11618 (2003).
180. M. Thomas, J. J. Lu, Q. Ge, C. Zhang, J. Chen, and A. M. Klibanov, Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. USA 102, 5679 (2005).
181. M. Thomas, J. J. Lu, C. Zhang, J. Chen, and A. M. Klibanov, Identification of novel superior polycationic vectors for gene delivery by high-throughput synthesis and screening of a combinatorial library. Pharm. Res. 24, 1564 (2007).
182. L. Wightman, R. Kircheis, V. Rössler, S. Carotta, R. Ruzicka, M. Kursa, and E. Wagner, Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene. Med. 3, 362 (2001).
183. S. Zhang, B. Zhao, H. Jiang, B. Wang, and B. Ma, Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control Release 123, 1 (2007).
184. O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J.-P. Behr, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. USA 92, 7297 (1995).
185. A. Philipp, X. Zhao, P. Tarcha, E. Wagner, and A. Zintchenko, Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjug. Chem. 20, 2055 (2009).
186. D. Jere, R. Arote, H.-L. Jiang, Y.-K. Kim, M.-H. Cho, and C.-S. Cho, Bioreducible polymers for efficient gene and siRNA delivery. Biomed. Mater. 4, 025020 (2009).
187. M. Breunig, C. Hozsa, U. Lungwitz, K. Watanabe, I. Umeda, H. Kato, and A. Goepferich, Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: Disulfide bonds boost intracellular release of the cargo. J. Control Release 130, 57 (2008).
188. A. Beyerle, A. Braun, O. Merkel, F. Koch, T. Kissel, and T. Stoeger, Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J. Control Release 151, 51 (2011).
189. H. S. Nalwa (ed.), Handbook of Nanostructured Materials and Nanotechnology, Academic Press, San Diego, CA (2000), Vols. 1-5.
190. C. Dufès, I. F. Uchegbu, and A. G. Schätzlein, Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57, 2177 (2005).
191. J. Zhou, J. Wu, N. Hafdi, J.-P. Behr, P. Erbacher, and L. Peng, PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem. Commun. 22, 2362 (2006).
192. A. G. Schatzlein, B. H. Zinselmeyer, A. Elouzi, C. Dufes, Y. T. A. Chim, C. J. Roberts, M. C. Davies, A. Munro, A. I. Gray, and I. F. Uchegbu, Preferential liver gene expression with polypropylenimine dendrimers. J. Control Release 101, 247 (2005).
193. O. Taratula, R. Savla, H. He, and T. Minko, Poly(propyleneimine) dendrimers as potential siRNA delivery nanocarrier: From structure to function. Int. J. Nanotechnol. 8, 36 (2011).
194. W. Cookson, The immunogenetics of asthma and eczema: A new focus on the epithelium. Nat. Rev. Immunol. 4, 978 (2004).
195. M. Ulanova, L. Puttagunta, M. Marcet-Palacios, M. Duszyk, U. Steinhoff, F. Duta, M.-K. Kim, Z. K. Indik, A. D. Schreiber, and A. D. Befus, Syk tyrosine kinase participates in β1-integrin signaling and inflammatory responses in airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 288, L497 (2005).
196. M. X. Shao, T. Nakanaga, and J. A. Nadel, Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-α-converting enzyme in human airway epithelial (NCI-H292) cells. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L420 (2004).
197. C. M. Kummitha, A. S. Malamas, and Z.-R. Lu, Advanced Delivery and Therapeutic Applications of RNAi, edited by K. Cheng and R. I. Mahato, John Wiley and Sons, Ltd., West Sussex, UK (2013), pp. 137-161.
198. T. Rojanarata, P. Opanasopit, S. Techaarpornkul, T. Ngawhirunpat, and U. Ruktanonchai, Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm. Res. 25, 2807 (2008).
199. H. Katas and H. O. Alpar, Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control Release 115, 216 (2006).
200. K. Roy, B. Ghosn, and S. P. Kasturi, Enhancing polysaccharide-mediated delivery of nucleic acids through functionalization with secondary and tertiary amines. Curr. Top. Med. Chem. 8, 331 (2008).
201. D. W. Lee, K.-S. Yun, H.-S. Ban, W. Choe, S. K. Lee, and K. Y. Lee, Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J. Control Release 139, 146 (2009).
202. S. Mao, W. Sun, and T. Kissel, Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 62, 12 (2010).
203. T. S.C. Li, T. Yawata, and K. Honke, Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy. Eur. J. Pharm. Sci. 52, 48 (2014).
204. R. Jayakumar, K. P. Chennazhi, R. A. A. Muzzarelli, H. Tamura, S. V. Nair, and N. Selvamurugan, Chitosan conjugated DNA nanoparticles in gene therapy. Carbohydr. Polym. 79, 1 (2010).
205. N. Saranya, A. Moorthi, S. Saravanan, M. P. Devi, and N. Selvamurugan, Chitosan and its derivatives for gene delivery. Int. J. Biol. Macromol. 48, 234 (2011).
206. X. Liu, K. A. Howard, M. Dong, M. Ø. Andersen, U. L. Rahbek, M. G. Johnsen, O. C. Hansen, F. Besenbacher, and J. Kjems, The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28, 1280 (2007).
207. K. Chaturvedi, K. Ganguly, A. R. Kulkarni, V. H. Kulkarni, M. N. Nadagouda, W. E. Rudzinski, and T. M. Aminabhavi, Cyclodextrin-based siRNA delivery nanocarriers: A state-of-the-art review. Expert Opin. Drug. Deliv. 8, 1455 (2011).
208. E. M. M. Del Valle, Cyclodextrins and their uses: A review. Process Biochem. 39, 1033 (2004).
209. M. E. Davis and M. E. Brewster, Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discovery 3, 1023 (2004).
210. F. Sallas and R. Darcy, Amphiphilic cyclodextrins - advances in synthesis and supramolecular chemistry. European J. Org. Chem. 2008, 957 (2008).
211. J. D. Heidel, Z. Yu, J. Y.-C. Liu, S. M. Rele, Y. Liang, R. K. Zeidan, D. J. Kornbrust, and M. E. Davis, Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 104, 5715 (2007).
212. P. Brahmamdam, E. Watanabe, J. Unsinger, K. C. Chang, W. Schierding, A. S. Hoekzema, T. T. Zhou, J. S. McDonough, H. Holemon, and J. D. Heidel, Targeted delivery of siRNA to cell death proteins in sepsis. Shock 32, 131 (2009).
213. H. Arima, F. Kihara, F. Hirayama, and K. Uekama, Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. Bioconjug Chem. 12, 476 (2001).
214. S. Hu-Lieskovan, J. D. Heidel, D. W. Bartlett, M. E. Davis, and T. J. Triche, Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984 (2005).
215. I. Ojea-Jimenez, J. Comenge, L. Garcia-Fernandez, Z. A. Megson, E. Casals, and V. F. Puntes, Engineered inorganic nanoparticles for drug delivery applications. Curr. Drug Metab. 14, 518 (2013).
216. G. Bao, S. Mitragotri, and S. Tong, Multifunctional nanoparticles for drug delivery and molecular imaging. Annu. Rev. Biomed. Eng. 15, 253 (2013).
217. N. L. Rosi, D. A. Giljohann, C. S. Thaxton, A. K. Lytton-Jean, M. S. Han, and C. A. Mirkin, Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027 (2006).
218. O. Taratula, O. Garbuzenko, R. Savla, Y. Andrew Wang, H. He, and T. Minko, Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug Deliv. 8, 59 (2011).
219. J. Zhao, X. Qiu, Z. Wang, J. Pan, J. Chen, and J. Han, Application of quantum dots as vectors in targeted survivin gene siRNA delivery. Onco. Targets Ther. 6, 303 (2013).
220. S. Beg, M. Rizwan, A. M. Sheikh, M. S. Hasnain, K. Anwer, and K. Kohli, Advancement in carbon nanotubes: Basics, biomedical applications and toxicity. J. Pharm. Pharmacol. 63, 141 (2011).
221. S. J. Tan, P. Kiatwuthinon, Y. H. Roh, J. S. Kahn, and D. Luo, Engineering nanocarriers for siRNA delivery. Small 7, 841 (2011).
222. D. A. Giljohann, D. S. Seferos, A. E. Prigodich, P. C. Patel, and C. A. Mirkin, Gene regulation with polyvalent siRNA-nanoparticle conjugates. J. Am. Chem. Soc. 131, 2072 (2009).
223. S. H. Lee, K. H. Bae, S. H. Kim, K. R. Lee, and T. G. Park, Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. Int. J. Pharm. 364, 94 (2008).
224. Y. Lee, S. H. Lee, J. S. Kim, A. Maruyama, X. Chen, and T. G. Park, Controlled synthesis of PEI-coated gold nanoparticles using reductive catechol chemistry for siRNA delivery. J. Control Release 155, 3 (2011).
225. G. B. Braun, A. Pallaoro, G. Wu, D. Missirlis, J. A. Zasadzinski, M. Tirrell, and N. O. Reich, Laser-activated gene silencing via gold nanoshell-siRNA conjugates. ACS Nano 3, 2007 (2009).
226. T. S. Sreeprasad and T. Pradeep, Springer Handbook of Nanomaterials, edited by R. Vajtai, Springer, Verlag, Berlin, Heidelberg (2013), Vol. 36, pp. 303-388.
227. D. Pissuwan, T. Niidome, and M. B. Cortie, The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J. Control Release 149, 65 (2011).
228. M. J. Santos-Martinez, K. Rahme, J. J. Corbalan, C. Faulkner, J. D. Holmes, L. Tajber, C. Medina, and M. W. Radomski, Pegylation increases platelet biocompatibility of gold nanoparticles. J. Biomed. Nanotechnol. 10, 1004 (2014).
229. A. C. Bonoiu, S. D. Mahajan, H. Ding, I. Roy, K.-T. Yong, R. Kumar, R. Hu, E. J. Bergey, S. A. Schwartz, and P. N. Prasad, Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc. Natl. Acad. Sci. USA 106, 5546 (2009).
230. A. C. Bonoiu, E. J. Bergey, H. Ding, R. Hu, R. Kumar, K.-T. Yong, P. N. Prasad, S. Mahajan, K. E. Picchione, and A. Bhattacharjee, Gold nanorod-siRNA induces efficient in vivo gene silencing in the rat hippocampus. Nanomedicine 6, 617 (2011).
231. C. C. Berry, and A. S. G. Curtis, Functionalisation of magnetic nanoparticles for applications in biomedicine. J. Phys. D Appl. Phys. 36, R198 (2003).
232. P. Tartaj, M. D. P. Morales, S. Veintemillas-Verdaguer, T. González-Carreño, and C. J. Serna, The preparation of magnetic nanoparticles for applications in biomedicine. J. Phys. D Appl. Phys. 36, R182 (2003).
233. Z. Saiyed, S. Telang, and C. Ramchand, Application of magnetic techniques in the field of drug discovery and biomedicine. Biomagn. Res. Technol. 1, 2 (2003).
234. U. Schillinger, T. Brill, C. Rudolph, S. Huth, S. Gersting, F. Krötz, J. Hirschberger, C. Bergemann, and C. Plank, Advances in magnetofection-magnetically guided nucleic acid delivery. J. Magn. Magn. Mater. 293, 501 (2005).
235. G. Gupta, S. Arora, S. Singh, and N. Singh, Advances in magnetofection-magnetically guided nucleic acid delivery: A review. Management 1, 37 (2013).
236. O. Mykhaylyk, D. Vlaskou, N. Tresilwised, P. Pithayanukul, W. Möller, and C. Plank, Magnetic nanoparticle formulations for DNA and siRNA delivery. J. Magn. Magn. Mater. 311, 275 (2007).
237. E. Caci, R. Melani, N. Pedemonte, G. Yueksekdag, R. Ravazzolo, J. Rosenecker, L. J. Galietta, and O. Zegarra-Moran, Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. Am. J. Respir. Cell Mol. Biol. 40, 211 (2009).
238. K. H. Bae, K. Lee, C. Kim, and T. G. Park, Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 32, 176 (2011).
239. H. S. Nalwa (ed.), Encyclopedia of Nanoscience and Nanotechnology, Volumes 1-25, American Scientific Publishers, Los Angeles, CA (2004/2011).
240. M. V. Yezhelyev, L. Qi, R. M. O'Regan, S. Nie, and X. Gao, Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc. 130, 9006 (2008).
241. V. Biju, T. Itoh, and M. Ishikawa, Delivering quantum dots to cells: Bioconjugated quantum dots for targeted and nonspecific extracellular and intracellular imaging. Chem. Soc. Rev. 39, 3031 (2010).
242. A. M. Derfus, A. A. Chen, D.-H. Min, E. Ruoslahti, and S. N. Bhatia, Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem. 18, 1391 (2007).
243. G. Büchel, M. Grün, K. K. Unger, A. Matsumoto, and T. Kazuo, Tailored syntheses of nanostructured silicas: Control of particle morphology, particle size and pore size. Supramol. Sci. 5, 253 (1998).
244. W. X. Mai, T. Xia, and H. Meng, Advanced Delivery and Therapeutic Applications of RNAi, edited by K. Cheng and R. I. Mahato, John Wiley and Sons, Ltd., West Sussex, UK (2013), pp. 187-205.
245. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J. I. Zink, and A. E. Nel, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4, 4539 (2010).
246. A. M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, and H. He, Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5, 2673 (2009).
247. T. Xia, M. Kovochich, M. Liong, H. Meng, S. Kabehie, S. George, J. I. Zink, and A. E. Nel, Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3, 3273 (2009).
248. K. Cheng and R. I. Mahato (eds.), Advanced Delivery and Therapeutic Applications of RNAi, John Wiley and Sons, Ltd., West Sussex, UK (2013).
249. D. A. Rey, C. A. Batt, and J. C. Miller, Carbon nanotubes in biomedical applications. Nanotech. L. and Bus. 3, 263 (2006).
250. J.-M. Lee, T.-J. Yoon, and Y.-S. Cho, Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed. Res. Int. 2013, 10 (2013).
251. D. Cai, J. M. Mataraza, Z.-H. Qin, Z. Huang, J. Huang, T. C. Chiles, D. Carnahan, K. Kempa, and Z. Ren, Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nat. Methods 2, 449 (2005).
252. D. Pantarotto, R. Singh, D. McCarthy, M. Erhardt, J. P. Briand, M. Prato, K. Kostarelos, and A. Bianco, Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew. Chem. 116, 5354 (2004).
253. Z. Liu, M. Winters, M. Holodniy, and H. Dai, siRNA Delivery into Human T Cells and Primary Cells with Carbon-Nanotube Transporters. Angew. Chem., Int. Ed. 46, 2023 (2007).
254. X. Wang, J. Ren, and X. Qu, Targeted RNA interference of Cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous Leukemia K562 cells. ChemMedChem. 3, 940 (2008).
255. M. Ladeira, V. Andrade, E. Gomes, C. Aguiar, E. Moraes, J. Soares, E. Silva, R. Lacerda, L. Ladeira, and A. Jorio, Highly efficient siRNA delivery system into human and murine cells using single-wall carbon nanotubes. Nanotechnology 21, 385101 (2010).
256. J. E. Podesta, K. T. Al-Jamal, M. A. Herrero, B. Tian, H. Ali-Boucetta, V. Hegde, A. Bianco, M. Prato, and K. Kostarelos, Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 5, 1176 (2009).
257. A. K. Varkouhi, S. Foillard, T. Lammers, R. M. Schiffelers, E. Doris, W. E. Hennink, and G. Storm, SiRNA delivery with functionalized carbon nanotubes. Int. J. Pharm. 416, 419 (2011).
258. A. Maitra, Calcium phosphate nanoparticles: Second-generation nonviral vectors in gene therapy. Expert Rev. Mol. Diagn. 5, 893 (2005).
259. Y. Kakizawa, S. Furukawa, and K. Kataoka, Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J. Control Release 97, 345 (2004).
260. J. Li, Y.-C. Chen, Y.-C. Tseng, S. Mozumdar, and L. Huang, Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control Release 142, 416 (2010).
261. F. Pittella, M. Zhang, Y. Lee, H. J. Kim, T. Tockary, K. Osada, T. Ishii, K. Miyata, N. Nishiyama, and K. Kataoka, Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 32, 3106 (2011).
262. X. He, T. Liu, Y. Chen, D. Cheng, X. Li, Y. Xiao, and Y. Feng, Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther. 15, 193 (2008).
263. S. Chono, S. D. Li, C. C. Conwell, and L. Huang, An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 131, 64 (2008).
264. Y. Chen, J. Sen, S. R. Bathula, Q. Yang, R. Fittipaldi, and L. Huang, Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm. 6, 696 (2009).
265. S. Taetz, A. Bochot, C. Surace, S. Arpicco, J.-M. Renoir, U. F. Schaefer, V. Marsaud, S. Kerdine- Roemer, C.-M. Lehr, and E. Fattal, Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 19, 103 (2009).
266. M. Saad, O. B. Garbuzenko, and T. Minko, Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 3, 761 (2008).
267. K. A. Howard, U. L. Rahbek, X. Liu, C. K. Damgaard, S. Z. Glud, M. O. Andersen, M. B. Hovgaard, A. Schmitz, J. R. Nyengaard, F. Besenbacher, and J. Kjems, RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476 (2006).
268. H. Chen, M. Munakata, and M. Amishima, Gamma-interferon modifies guinea pig airway functions in vitro. Eur. Respir. J. 7, 74 (1994).
269. E. Kawata, E. Ashihara, S. Kimura, K. Takenaka, K. Sato, R. Tanaka, A. Yokota, Y. Kamitsuji, M. Takeuchi, and J. Kuroda, Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol. Cancer Ther. 7, 2904 (2008).
270. J. Nguyen, T. W. Steele, O. Merkel, R. Reul, and T. Kissel, Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J Control Release 132, 243 (2008).
271. S. A. Moschos, S. W. Jones, M. M. Perry, A. E. Williams, J. S. Erjefalt, J. J. Turner, P. J. Barnes, B. S. Sproat, M. J. Gait, and M. A. Lindsay, Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 18, 1450 (2007).
272. J.-H. Lee, K. Lee, S. H. Moon, Y. Lee, T. G. Park, and J. Cheon, All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew.Chem. Int. Ed. 48, 4174 (2009).
273. J. Shen, R. Samul, R. Silva, H. Akiyama, H. Liu, Y. Saishin, S. Hackett, S. Zinnen, K. Kossen, and K. Fosnaugh, Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13, 225 (2005).
274. A. Kamali, and M. Holodniy, Influenza treatment and prophylaxis with neuraminidase inhibitors: A review. Infect. Drug Resist. 6, 187 (2013).
275. D. Mertz, T. H. Kim, J. Johnstone, P.-P. Lam, S. P. Kuster, S. A. Fadel, D. Tran, E. Fernandez, N. Bhatnagar, and M. Loeb, Populations at risk for severe or complicated influenza illness: Systematic review and meta-analysis. Br. Med. J. 347, f5061 (2013).
276. Q. Ge, M. T. McManus, T. Nguyen, C.-H. Shen, P. A. Sharp, H. N. Eisen, and J. Chen, RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 100, 2718 (2003).
277. S. M. Tompkins, C.-Y. Lo, T. M. Tumpey, and S. L. Epstein, Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101, 8682 (2004).
278. Q. Ge, H. N. Eisen, and J. Chen, Use of siRNAs to prevent and treat influenza virus infection. Virus Res. 102, 37 (2004).
279. M. Nakazawa, S.-E. Kadowaki, I. Watanabe, Y. Kadowaki, M. Takei, and H. Fukuda, PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Res. 78, 194 (2008).
280. W. Zhang, H. Yang, X. Kong, S. Mohapatra, H. San Juan-Vergara, G. Hellermann, S. Behera, R. Singam, R. F. Lockey, and S. S. Mohapatra, Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11, 56 (2004).
281. X. Kong, W. Zhang, R. F. Lockey, A. Auais, G. Piedimonte, and S. S. Mohapatra, Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet. Vaccines Ther. 5, 4 (2007).
282. Z. Wang, L. Ren, X. Zhao, T. Hung, A. Meng, J. Wang, and Y.-G. Chen, Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J. Virol. 78, 7523 (2004).
283. World Health Organisation, http://www.who.int/csr/don/2013-12-27/en/ index.html, Accessed December 19 (2013).
284. C.-J. Wu, H.-W. Huang, C.-Y. Liu, C.-F. Hong, and Y.-L. Chan, Inhibition of SARS-CoV replication by siRNA. Antiviral Res. 65, 45 (2005).
285. Q. Tang, B. Li, M. Woodle, and P. Y. Lu, Application of siRNA against SARS in the rhesus macaque model, RNAi, edited by S. Barik, Humana Press, Totowa, NJ (2008), Vol. 442, pp. 139-158.
286. World Health Organisation, http://www.who.int/tb/publications/global- report/gtbr13-executive-summary.pdf, Accessed December 15 (2013).
287. Mayo Foundation for Medical Education and Research http://www.mayoclinic. com/health/tuberculosis/DS00372/DSECTION=treatments-and-drugs, Accessed December 24 (2013).
288. US Department of Energy, Research News, http://www.eurekalert.org/ features/doe/2004-11/ddoe-sdg111104.php, Accessed December 30 (2013).
289. Genome Web, http://www.genomeweb.com/rnai/researcher-develops-rna-dna- hybrid-may-offer-advantages-over-sirna, Accessed January 1 (2014).
290. S. Lucchini, G. Rowley, M. D. Goldberg, D. Hurd, M. Harrison, and J. C. Hinton, H-NS mediates the silencing of laterally acquired genes in bacteria. PLoS Pathog 2, e81 (2006).
291. A. G. Rosas-Taraco, D. M. Higgins, J. Sánchez-Campillo, E. J. Lee, I. M. Orme, and M. González-Juarrero, Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in mycobacterium tuberculosis infected mice. Tuberculosis 91, 98 (2011).
292. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, Global cancer statistics. CA. Cancer J. Clin. 61, 69 (2011).
293. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893 (2010).
294. D. Behera, Epidemiology of lung cancer - Global and Indian perspective. J. Indian Acad. Clin. Med. 13, 131 (2012).
295. J. Jiang, X. Liang, X. Zhou, R. Huang, Z. Chu, and Q. Zhan, Non-platinum doublets were as effective as platinum-based doublets for chemotherapy- naïve advanced non-small-cell lung cancer in the era of third-generation agents. J. Cancer Res. Clin. Oncol. 139, 25 (2013).
296. M. E. Abazeed, D. J. Adams, K. E. Hurov, P. Tamayo, C. J. Creighton, D. Sonkin, A. O. Giacomelli, C. Du, D. F. Fries, and K.-K. Wong, Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 73, 6289 (2013).
297. A. Ihbe-Heffinger, B. Paessens, K. Berger, M. Shlaen, R. Bernard, C. von Schilling, and C. Peschel, The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care-an observational analysis on non-small-cell lung cancer patients. Support. Care Cancer 21, 1665 (2013).
298. A.-Q. Dong, M.-J. Kong, Z.-Y. Ma, J.-F. Qian, and X.-H. Xu, Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice. Cell Biol. Int. 31, 500 (2007).
299. H. Xia, C.-H. Yu, Y. Zhang, J. Yu, J. Li, W. Zhang, B. Zhang, Y. Li, and N. Guo, EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. Oncol. Lett. 4, 135 (2012).
300. M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, and N. Röder, Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68, 9788 (2008).
301. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M. D. Waterfield, Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615 (2001).
302. A. Santel, M. Aleku, N. Röder, K. Möpert, B. Durieux, O. Janke, O. Keil, J. Endruschat, S. Dames, and C. Lange, Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin. Cancer Res. 16, 5469 (2010).
303. X. Xu, S. Liu, B. Lei, W. Li, N. Lin, W. Sheng, A. Huang, and H. Shen, Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G. Mol. Cell. Biochem. 383, 1 (2013).
304. X. Xue and X. Liang, Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin. J. Cancer 31, 100 (2012).
305. X. Dong and R. J. Mumper, Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine 5, 597 (2010).
306. A. Shapira, Y. D. Livney, H. J. Broxterman, and Y. G. Assaraf, Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist. Updat. 14, 150 (2011).
307. C. V. Dang and G. L. Semenza, Oncogenic alterations of metabolism. Trends Biochem. Sci. 24, 68 (1999).
308. A. Di Paolo and G. Bocci, Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification. Curr. Oncol. Rep. 9, 109 (2007).
309. C.-H. Heldin, K. Rubin, K. Pietras, and A. Östman, High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806 (2004).
310. O. Trédan, C. M. Galmarini, K. Patel, and I. F. Tannock, Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441 (2007).
311. D. S. Cowan and I. F. Tannock, Factors that influence the penetration of methotrexate through solid tissue. Int. J. Cancer 91, 120 (2001).
312. C. de L Davies, D. Berk, A. Pluen, and R. Jain, Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 86, 1639 (2002).
313. P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, and R. K. Jain, Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497 (2000).
314. S. Vinogradov and X. Wei, Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine 7, 597 (2012).
315. T. P. Padera, B. R. Stoll, J. B. Tooredman, D. Capen, E. di Tomaso, and R. K. Jain, Cancer cells compress intratumour vessels. Nature 427, 695 (2004).
316. K. M. Comerford, T. J. Wallace, J. Karhausen, N. A. Louis, M. C. Montalto, and S. P. Colgan, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62, 3387 (2002).
317. G. L. Wang and G. L. Semenza, Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230 (1995).
318. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. Annu. Rev. Pharmacol. Toxicol. 39, 361 (1999).
319. D. M. Townsend and K. D. Tew, The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369 (2003).
320. A. Eastman and N. Schulte, Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 27, 4730 (1988).
321. M. Kavallaris, D. Kuo, C. A. Burkhart, D. L. Regl, M. D. Norris, M. Haber, and S. B. Horwitz, Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100, 1282 (1997).
322. T. Sethi, R. C. Rintoul, S. M. Moore, A. C. MacKinnon, D. Salter, C. Choo, E. R. Chilvers, I. Dransfield, S. C. Donnelly, and R. Strieter, Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662 (1999).
323. S. Green, A. Frankel, and R. Kerbel, Adhesion-dependent multicellular drug resistance. Anticancer Drug Des. 14, 153 (1999).
324. P. J. Morin, Drug resistance and the microenvironment: Nature and nurture. Drug Resist. Updat. 6, 169 (2003).
325. S. Pai, Y. Lin, B. Macaes, A. Meneshian, C. Hung, and T. Wu, Prospects of RNA interference therapy for cancer. Gene Ther. 13, 464 (2005).
326. S. Weinstein and D. Peer, RNAi nanomedicines: Challenges and opportunities within the immune system. Nanotechnology 21, 232001 (2010).
327. D. M. Glover, I. M. Hagan, and Á. A. Tavares, Polo-like kinases: A team that plays throughout mitosis. Genes Dev. 12, 3777 (1998).
328. K. Strebhardt, Encyclopedia of Molecular Medicine, edited by A. M. Campbell, John Wiley and Sons, Inc., New York (2001).
329. W.-P. Su, F.-Y. Cheng, D.-B. Shieh, C.-S. Yeh, and W.-C. Su, PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int. J. Nanomedicine 7, 4269 (2012).
330. H. Yu, Z. Xu, X. Chen, L. Xu, Q. Yin, Z. Zhang, and Y. Li, Reversal of Lung Cancer Multidrug Resistance by pH-Responsive Micelleplexes Mediating Co-Delivery of siRNA and Paclitaxel. Macromol. Biosci. 14, 100 (2013).
331. G. Chen, P. Kronenberger, E. Teugels, I. A. Umelo, and J. De Grève, Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: The effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 10, 15 (2012).
332. S. K. Murphy and J. W. Hollingsworth, Stress: A possible link between genetics, epigenetics, and childhood asthma. Am. J. Respir. Crit. Care Med. 187, 563 (2013).
333. M. Anguita, Trends and new developments in asthma treatment. Nurse Prescribing 11, 318 (2013).
334. J. Bousquet and N. G. Khaltaev (eds.), Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach, World Health Organisation (2007).
335. K. D. Jackson, L. D. Howie, and L. J. Akinbami, Trends in allergic conditions among children: United States, 1997-2011. NCHS Data Brief 121, 1 (2013).
336. V. Goyal and P. D. Sly, How children with asthma breathe: Have we been overlooking a problem? Eur. Respir. J. 41, 1008 (2013).
337. Y. Kanemitsu, H. Matsumoto, K. Izuhara, Y. Tohda, H. Kita, T. Horiguchi, K. Kuwabara, K. Tomii, K. Otsuka, and M. Fujimura, Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J. Allergy Clin. Immunol. 132, 305 (2013).
338. J. R. Murdoch and C. M. Lloyd, Chronic inflammation and asthma. Mutat. Res. 690, 24 (2010).
339. I. M. Adcock and G. Caramori, Cross-talk between proinflammatory transcription factors and glucocorticoids. Immunol. Cell Biol. 79, 376 (2001).
340. M. Wills-Karp, The gene encoding interleukin-13: A susceptibility locus for asthma and related traits. Respir. Res. 1, 19 (2000).
341. S. Sel, W. Henke, A. Dietrich, U. Herz, and H. Renz, Treatment of allergic asthma by targeting transcription factors using nucleic-acid based technologies. Curr. Pharm. Des. 12, 3293 (2006).
342. G. D. Healey, N. Evans, J. M. Hopkin, G. Davies, and W. Walker, Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma. J. Cell. Mol. Med. 17, 356 (2013).
343. L. Zhu, Q. Zhu, X. Zhang, and H. Wang, The correlation analysis of two common polymorphisms in STAT6 gene and the risk of asthma: A meta-analysis. PLoS One 8, e67657 (2013).
344. F. Levi-Schaffer, I. Bachelet, A. Munitz, and M. E. Rothenberg, Novel therapeutic target and diagnostic marker for asthma and related conditions, in, US Patent App. 13/780,994, July 11 (2013).
345. H. Y. Huang and B.-L. Chiang, siRNA as a therapy for asthma. Curr. Opin. Mol. Ther. 11, 652 (2009).
346. H. Meinicke, Y. Darcan, and E. Hamelmann, Targeting allergic airway diseases by siRNA: An option for the future?. Curr. Mol. Med. 9, 483 (2009).
347. F. D. Popescu, Antisense-and RNA interference-based therapeutic strategies in allergy. J. Cell. Mol. Med. 9, 840 (2005).
348. Z.-Y. Huang, M.-K. Kim, T.-H. Kim-Han, Z. K. Indik, and A. D. Schreiber, Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma. Mol. Immunol. 53, 52 (2013).
349. G. R. Stenton, M.-K. Kim, O. Nohara, C.-F. Chen, N. Hirji, F. L. Wills, M. Gilchrist, P.-H. Hwang, J.-G. Park, and W. Finlay, Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J. Immunol. 164, 3790 (2000).
350. S. Miyamoto, N. Hattori, T. Senoo, Y. Onari, H. Iwamoto, M. Kanehara, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, A. Yokoyama, and N. Kohno, Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 301, L908 (2011).
351. C. Qiu, W. K. Peng, F. Shi, and T. Zhang, Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene. Genet. Mol. Res. 11, 3236 (2012).
352. Y. Darcan-Nicolaisen, H. Meinicke, G. Fels, O. Hegend, A. Haberland, A. Kühl, C. Loddenkemper, M. Witzenrath, S. Kube, and W. Henke, Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. The Journal of Immunology 182, 7501 (2009).
353. X. Kong, G. Hellermann, W. Zhang, P. Jena, M. Kumar, A. Behera, S. Behera, R. Lockey, and S. Mohapatra, Chitosan interferon-gamma nanogene therapy for lung disease: Modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin. Immunol. 4, 95 (2008).
354. I. W. Choi, D. K. Kim, H. M. Ko, and H. K. Lee, Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits established asthmatic reaction in mice. Int. Immunopharmacol. 4, 1817 (2004).
355. N. A. Molfino, Genetics of COPD. Chest 125, 1929 (2004).
356. F. J. Martinez, J. F. Donohue, and S. I. Rennard, The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 378, 1027 (2011).
357. K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, and C. van Weel, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532 (2007).
358. S.-L. Huang, C.-H. Su, and S.-C. Chang, Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am. J. Respir. Crit. Care Med. 156, 1436 (1997).
359. K. Aoshiba, N. Yokohori, and A. Nagai, Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am. J. Respir. Cell Mol. Biol. 28, 555 (2003).
360. Y. Kasahara, R. M. Tuder, L. Taraseviciene-Stewart, T. D. Le Cras, S. Abman, P. K. Hirth, J. Waltenberger, and N. F. Voelkel, Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106, 1311 (2000).
361. P. J. Barnes and R. Stockley, COPD: Current therapeutic interventions and future approaches. Eur. Respir. J. 25, 1084 (2005).
362. A. Banerjee, C. Koziol-White, and R. Panettieri, Jr, p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. Curr. Opin. Pharmacol. 12, 287 (2012).
363. N. Vij, Nano-based theranostics for chronic obstructive lung diseases: Challenges and therapeutic potential. Expert Opin. Drug. Deliv. 8, 1105 (2011).
364. J. F. Chmiel, M. Berger, and M. W. Konstan, The role of inflammation in the pathophysiology of CF lung disease. Clin. Rev. Allergy Immunol. 23, 5 (2002).
365. G. Yueksekdag, M. Drechsel, M. Rossner, C. Schmidt, M. Kormann, M. C. Illenyi, C. Rudolph, and J. Rosenecker, Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways. Eur. J. Pharm. Biopharm. 75, 305 (2010).
366. C. Kelly, A. B. Yadav, P. J. McKiernan, C. M. Greene, and S.-A. Cryan, Advanced Delivery and Therapeutic Applications of RNAi, edited by K. Cheng and R. I. Mahato, John Wiley and Sons, Ltd., West Sussex, UK (2013), pp. 391-416.
367. P. J. Wolters, H. R. Collard, and K. D. Jones, Pathogenesis of idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 9, 157 (2013).
368. W. Matsuyama, M. Watanabe, Y. Shirahama, R. Hirano, H. Mitsuyama, I. Higashimoto, M. Osame, and K. Arimura, Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation. J. Immunol. 176, 1928 (2006).
369. T. H. Kim, S.-H. Kim, J.-Y. Seo, H. Chung, H. J. Kwak, S.-K. Lee, H. J. Yoon, D. H. Shin, S. S. Park, and J. W. Sohn, Blockade of the Wnt/β-catenin pathway attenuates bleomycin-induced pulmonary fibrosis. Tohoku J. Exp. Med. 223, 45 (2011).
370. D. K. Sung, W. H. Kong, K. Park, J. H. Kim, M. Y. Kim, H. Kim, and S. K. Hahn, Noncovalenly PEGylated CTGF siRNA/PDMAEMA complex for pulmonary treatment of bleomycin-induced lung fibrosis. Biomaterials 34, 1261 (2013).
371. A. R. Simon, V. Karsten, R. Meyers, J. Cehelsky, J. Gollob, A. Vaishnaw, and S. Nochur, RNA Interference from Biology to Therapeutics, edited by K. A. Howard, Springer, New York (2013), pp. 315-328.
372. M. R. Zamora, M. Budev, M. Rolfe, J. Gottlieb, A. Humar, J. DeVincenzo, A. Vaishnaw, J. Cehelsky, G. Albert, and S. Nochur, RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 183, 531 (2011).
373. Alnylam Pharmaceuticals, http://www.alnylam.com/Programs-and-Pipeline/ Partner-Programs/index.php, Accessed December 31 (2013).
374. W. Zhang and R. A. Tripp, RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J. Virol. 82, 12221 (2008).
375. ZaBeCor, http://www.zabecor.com/news/news092209.php, Accessed December 30 (2013).
376. J. A. Cavagnaro, Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat. Rev. Drug Discovery 1, 469 (2002).
377. S. L. Lee, P. Brown, J. Wang, and R. T. Dorsaml, Advanced Delivery and Therapeutic Applications of RNAi, edited by K. Cheng and R. I. Mahato, John Wiley and Sons, Ltd., West Sussex, UK (2013), pp. 63-81.
378. R. M. Blaese, K. W. Culver, A. D. Miller, C. S. Carter, T. Fleisher, M. Clerici, G. Shearer, L. Chang, Y. Chiang, and P. Tolstoshev, T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270, 475 (1995).
379. C. Sheridan, Gene therapy finds its niche. Nat. Biotechnol. 29, 121 (2011).
380. L. E. Black, J. G. Farrelly, J. A. Cavagnaro, C. H. Ahn, J. J. DeGeorge, A. S. Taylor, A. F. DeFelice, and A. Jordan, Regulatory considerations for oligonucleotide drugs: Updated recommendations for pharmacology and toxicology studies. Antisense Res. Dev. 4, 299 (1994).
381. Wiley, http://www.wiley.com//legacy/wileychi/genmed/clinical/, Accessed December 30 (2013).
382. L. E. Black, J. J. DeGeorge, J. A. Cavagnaro, A. Jordan, and C. H. Ahn, Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res. Dev. 3, 399 (1993).
383. M. J. Derelanko and M. A. Hollinger (eds.), CRC Handbook of Toxicology, CRC Press, Danvers, MA, USA (2002).
384. C. E. Thomas, A. Ehrhardt, and M. A. Kay, Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346 (2003).
385. A. Beyerle, T. Kissel, and T. Stoeger, Non-Viral Gene Therapy, edited by X. Yuan, Intechopen, Rijeka, Croatia (2011), pp. 481-498.
386. A. Elouahabi and J.-M. Ruysschaert, Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. 11, 336 (2005).
387. H. Gershon, R. Ghirlando, S. B. Guttman, and A. Minsky, Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry 32, 7143 (1993).
388. M. Ruponen, S. Ylä-Herttuala, and A. Urtti, Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: Physicochemical and transfection studies. Biochim. Biophys. Acta 1415, 331 (1999).
389. Y. Zhao, D. Zhi, and S. Zhang, Non-Viral Gene Therapy, edited by X. Yuan, Intechopen, Rijeka, Croatia (2011), pp. 293-318.
390. E. White, R. Cipriani, P. Sabbatini, and A. Denton, Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J. Virol. 65, 2968 (1991).
391. W. F. Anderson, Assessment of adenoviral vector safety and toxicity: Report of the national institutes of health recombinant DNA advisory committee. Hum. Gene Ther. 13, 3 (2002).
392. E. Marshall, Gene therapy death prompts review of adenovirus vector. Science 286, 2244 (1999).
393. S. Hacein-Bey-Abina, C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J.-L. Villeval, C. C. Fraser, and M. Cavazzana-Calvo, A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255 (2003).
394. E. Check, Gene therapy: A tragic setback. Nature 420, 116 (2002).
395. J. Kaiser, Seeking the cause of induced leukemias in X-SCID trial. Science 299, 495 (2003).
396. P. Pinnaduwage, L. Schmitt, and L. Huang, Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochim. Biophys. Acta 985, 33 (1989).
397. S. Kawakami, F. Yamashita, M. Nishikawa, Y. Takakura, and M. Hashida, Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes. Biochem. Biophys. Res. Commun. 252, 78 (1998).
398. I. Solodin, C. S. Brown, M. S. Bruno, C.-Y. Chow, E.-H. Jang, R. J. Debs, and T. D. Heath, A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery. Biochemistry 34, 13537 (1995).
399. A. A. Meekel, A. Wagenaar, J. S¡misterová, J. E. Kroeze, P. Haadsma, B. Bosgraaf, M. Stuart, A. Brisson, M. Ruiters, and D. Hoekstra, Synthesis of pyridinium amphiphiles used for transfection and some characteristics of amphiphile/DNA complex formation. Eur. J. Org. Chem. 2000, 665 (2000).
400. M. A. Ilies, W. A. Seitz, M. T. Caproiu, M. Wentz, R. E. Garfield, and A. T. Balaban, Pyridinium-based cationic lipids as gene-transfer agents. Eur. J. Org. Chem. 2003, 2645 (2003).
401. V. Floch, S. Loisel, E. Guenin, A. C. Hervé, J. C. Clément, J. J. Yaouanc, H. des Abbayes, and C. Férec, Cation substitution in cationic phosphonolipids: A new concept to improve transfection activity and decrease cellular toxicity. J. Med. Chem. 43, 4617 (2000).
402. H. Farhood, R. Bottega, R. M. Epand, and L. Huang, Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochim. Biophys. Acta 1111, 239 (1992).
403. D. Liu, W. Qiao, Z. Li, S. Zhan, and L. Cheng, Synthesis and characterization of a series of carbamate-linked cationic lipids for gene delivery. Lipids 40, 839 (2005).
404. C. R. Dass, Vehicles for oligonucleotide delivery to tumours. J. Pharm. Pharmacol. 54, 3 (2002).
405. Y. H. Kim, J. H. Park, M. Lee, Y.-H. Kim, T. G. Park, and S. W. Kim, Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J. Control Release 103, 209 (2005).
406. W. Godbey, K. K. Wu, and A. G. Mikos, Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials 22, 471 (2001).
407. C. W. Pouton, P. Lucas, B. J. Thomas, A. N. Uduehi, D. A. Milroy, and S. H. Moss, Polycation-DNA complexes for gene delivery: A comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J. Control Release 53, 289 (1998).
408. L. Shewring, L. Collins, S. L. Lightman, S. Hart, K. Gustafsson, and J. W. Fabre, A nonviral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins 1. Transplantation 64, 763 (1997).
409. H. Eliyahu, A. Joseph, T. Azzam, Y. Barenholz, and A. J. Domb, Dextran-spermine-based polyplexes-evaluation of transgene expression and of local and systemic toxicity in mice. Biomaterials 27, 1636 (2006).
410. F. Verbaan, G. Bos, C. Oussoren, M. Woodle, W. Hennink, and G. Storm, A comparative study of different cationic transfection agents for in vivo gene delivery after intravenous administration. STP Pharma. Sciences 14, 105 (2004).
411. M. G. Daniels, R. V. Bowman, I. A. Yang, R. Govindan, and K. M. Fong, An emerging place for lung cancer genomics in 2013. J. Thorac. Dis. 5, S491 (2013).